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Increased number of thromboxane 
A2-prostaglandin H2 platelet receptors in 
active unstable angina and causative role of 
enhanced thrombin formation 
The current study was designed to investigate the number and affinity of platelet thromboxane 
A2/prostaglandin H2 (TxA2/PGH2) receptors in patients with unstable angina and, if any, the role 
played by the increased thrombin formation that is a common finding in these patients. 
Measurements taken during active unstable angina but not those taken during inactive angina 
showed an increased number (p < 0.001), without changes in affinity, of platelet TxA2/PGH2 
receptors, evaluated as the binding capacity of iodine 125-PTA-OH, a stable TxA2 analogue. 
Moreover patients with active angina had higher plasma concentrations of fibrinopeptide A (FPA) 
(p < 0.0001), which were significantly related to the number of platelet TxA2/PGH2 receptors 
(r = 0.76; p < 0.01). Heparin infusion but not aspirin treatment promptly normalized the number of 
TxA2/PGH2 receptors and significantly reduced plasma FPA concentrations. In an in-vitro study 
thrombin in a concentration similar to that found in vivo significantly increased the number of 
platelet TxA2/PGH2 receptors (p < 0.01), whereas heparin did not affect TxA2/PGH2 receptors. 
These results have important therapeutic implications and indicate the preferential use of 
heparin rather than aspirin during the acute phase of unstable angina. (AM HEART J 
1995;129:873-9.) 
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Alessandro Costoli, MD, Debora Biagini, MD, Angela Migliorini, MD, and 
Gian Gastone Neri Serneri, MD Florence, Italy 
Several studies have shown that in patients with un- 
stable angina platelet activation is increased, 1  2 fre- 
quently resulting in enhanced thromboxane A2 
(TxA2) formation and increased platelet aggrega- 
tion.3, 4 Moreover, a decreased number of platelet re- 
ceptors for prostacyclin I25 (PGI2) and prostaglandin 
E16 has been found in patients with unstable angina 
and an increased density of platelet TxA2/pros- 
taglandin H2 (PGH2) receptors in patients with acute 
myocardial infarction. 7The increased TxA2 forma- 
tion by platelets in patients with unstable angina has 
been found to be associated with changes in the fatty 
acid content of platelet membranes s that might 
result in functional changes in platelet binding sites. 
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In addition to these functional changes in platelet 
activity, patients with unstable angina frequently 
show enhanced thrombin formation, as indicated by 
increased plasma concentrations of fibrinopeptide A 
(FPA). 911 Thus in patients with unstable angina 
links might exist among the altered fatty acid com- 
position of platelets, membrane changes in platelet 
functional activities, and increased thrombin gener- 
ation. The current study was designed to investigate 
in vivo and in vitro whether the number or affinity of 
platelet receptors for TxA2/PGH2 is changed in pa- 
tients with unstable angina and whether the in- 
creased thrombin formation may be responsible for 
any changes. 
METHODS 
Study population. Participating in the investigation 
were 21 patients with primary unstable angina with the 
most recent painful episode having occurred <24 hours be- 
fore admission to the hospital (active phase), 18 patients 
who had had unstable angina but who had been free of 
symptomatic orasymptomatic (by Holter monitoring) is- 
chemic episodes for ~8 weeks (inactive phase), and 11 pa- 
873 
May 1995 
874 Modest i  et al. American Heart Journal 
Table I. Patient characteristics 
Patients with unstable angina 
Control subjects Active Unactive Patients with effort 
(n = 33) (n --- 21) (n = 18) angina (n = 11) 
Age (yr) 58 _+ 9 
Weight (kg) 65 _ 10 
Fasting blood glucose (mg/dl) 103 _+ 6 
Triglycerides (mg/dl) 126 _+ 19 
Total cholesterol (mg/dl) 186 _ 32 
High-density lipoprotein cholesterol (mg/dl) 49 _+ 9 
Platelets (×106/ml) 240 _+ 36 
Megathrombocytes (%) 6.8 + 1.8 
Protein (mg/109 platelets) 3.7 + 0.3 
62+9 59_+ 10 61+_10 
69_+ 12 67+9 69_+ 12 
108_+5 105+4 109_+8 
141 + 33 132 _+ 15 145 +_ 23 
191 _+ 26 196 _+ 38 189 _+ 36 
45_ 1i 44_+ i2 39_+ 11 
233 _+ 36 229 _ 39 231 _+ 33 
10.1 _+ 2.2 7.1 _+ 1.8 6.9 _+ 1.9 
3.9 + 0.4 3.8 _+ 0.2 3.7 _+ 0.3 
tients with stable angina (effort angina). As control sub- 
jects 33 apparently healthy persons of similar ages were 
studied. None of the control subjects had taken any drugs 
for >__2 weeks. Patients with angina were excluded from the 
study if they had enzymatic or electrocardiographic (ECG) 
evidence of myocardial infarction; were older than 75 years; 
or had diabetes, immunologic disorders, or neoplastic dis- 
ease. Subjects also were excluded if they had undergone 
surgical or invasive procedures inthe month preceding the 
study. Characteristics of the subjects are reported in Table 
I. 
Unstable angina was defined as chest pain occurring at 
rest or on minimal effort (eg, washing, speaking, or comb- 
ing) without any increase in creatine kinase MB fraction, 
with ECG evidence of myocardial ischemia (transient ST- 
segment displacement >0.1 mV during chest pain), and 
with angiographic evidence of coronary artery disease. 
Platelet TxA2/PGH2 receptors were investigated when pa- 
tients with active angina were taking only nitrates (isosor- 
bide dinitrate, six 10 mg tablets daily) and before admin- 
istration of aspirin or heparin or other drugs. In eight pa- 
tients platelet TxA2/PGH2 receptors also were investigated 
before and after 48-hour continuous intravenous infusion 
of heparin, priming dose 5000 IU followed by 800 to 1000 
IU/hr. In another eight patients TxA2/PGH2 receptors 
were investigated before and after aspirin, 325 mg/day for 
3 days. 
In all patients coronary angiography was performed af- 
ter the assessment ofplatelet receptors. Ten of the 21 pa- 
tients with active-phase unstable angina were studied 
again 8 to 12 weeks later during the inactive phase. Eight 
additional patients with unstable angina in the inactive 
phase also were investigated atthis time. All patients in the 
inactive phase were taking nitrates (isosorbide dinitrate, 10 
mg tablets three or four times per day), and aspirin had 
been stopped >--2 weeks before the study. 
Stable effort angina was defined according to the follow- 
ing criteria: (1) typical angina on effort and no angina at 
rest during at least the previous 3 months; (2) no asymp- 
tomatic ischemic episodes at rest during 3-day Holter 
monitoring; (3) stable ischemic threshold uring at least 
three stress exercises in the week preceding the study; and 
(4) angiographic evidence (at least one stenosis >70% of 
vessel diameter) of coronary artery disease. Patients with 
effort angina had been taking nitrates for ___1 week before 
the study. All other drugs were stopped >__2 weeks previ- 
ously. Nine patients with stable effort angina nd 9 control 
subjects were studied again 8 to 12 weeks later. 
All patients gave informed consent to use of part of their 
blood samples for an experimental study. 
Blood sampling and platelet isolation. Blood samples 
(50 to 60 ml) were collected with a 19-gauge siliconized 
needle in a syringe containing indomethacin (10 #mol/L) 
and acid citrate dextrose (National Institutes of Health 
formula A) (15 % volume/volume). Washed platelets were 
prepared by sequential centrifugation a d resuspended in 
assay buffer (138 mmol/L NaC1, 5 mmol/L MgC12, 1 
mmol/L EGTA and 25 mmol/L Tris/HC1, pH 7.5) to 109 
platelets/ml as previously described. 5 
Platelet TxA2/PGH2 receptor assay, TxA2/PGH2 recep- 
tors were investigated with 9,11-dimethyl- methano-ll,12- 
methano-16(3[125I] -4-hydroxyphenyl)- 13,14-dihydro-13- 
aza-15-tetranor-TxA2 (1 5I-PTA-OH) (Amersham, Buck- 
inghamshire, Great Britain) (2000 Ci/mmol), a stable 
labeled analogue of TxA2, and with ONO11120, the unla- 
beled dehydroxylated form of 125I-PTA-OH (a gift from S. 
Narumiya, MD, Kyoto, Japan) as a cold displacer. In brief, 
5 X 107 washed platelets were incubated in a final volume 
of 0.2 ml for 10 minutes at room temperature with increas- 
ing concentrations of ONO11120 (0 to 4 × 10 -6 tool/L) and 
a fixed concentration f 125I-PTA-OH, 0.05 nmoI/L (final 
concentrations [fc]). Bound radioactivity was separated by 
rapid filtration under reduced pressure through glass mi- 
crofiber filters (GF/C, Whatman, Maidstone, England). 
Previous time course experiments showed that in these 
conditions binding equilibrium had been reached. 12 The 
entire washing procedure was completed within about 15 
seconds. Nonspecific binding was defined as the residual 
binding after the addition of ONO11120 2 x 10 -5 mol/L 
(fc). Nonspecific binding of 0.05 nmol/L 125I-PTA-OH was 
30 % to 40 % of total binding. The experiments were carried 
out in triplicate. 
The binding affinity (dissociation constant [Kd]) and 
maximum binding capacity (Bronx) were obtained from a 
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Fig. 1. Saturation curves and Scatcbard plots (inset) cor- 
rected for nonspecific binding in control subjects (open di- 
amonds), patients with unstable angina in active phase 
(open squares) and in inactive (solid diamonds) phase, and 
patients with effort stable angina (solid squares), plt, 
Platelets. 
nonlinear egression analysis of equilibrium binding per- 
formed by a computerized iterative, least-squares algorith- 
mic analysis on a microcomputer according to Scatchard. 13
Effects of thrombin on platelet 12SI-PTA-OH binding. 
To determine the effects of thrombin (from human plasma, 
SIGMA, St. Louis, Mo.) on platelet TxA2/PGH2 receptors, 
0.1 ml platelet suspension was incubated in a final volume 
of 0.2 ml with 125I-PTA-OH 0.05 nmol/L plus ON011120 
in increasing selected concentrations (0 to 4 × 10 -6  mol/L) 
in the presence and in the absence of thrombin in increas- 
ing concentrations (0,0.005, 0.01, and 0.05 U/ml). After a 
10-minute incubation at room temperature samples were 
processed as previously described. Similarly the effect of 
increasing concentrations of unfractionated sodium hepa- 
tin (Liquemin, Roche, Milan, Italy) (0 to 2 IU/ml) on 125I- 
PTA-OH binding to platelets was assessed. 
FPA assay. FPA was evaluated by enzyme-linked im- 
munosorbent assay according to Gaffney et al.14 and Soria 
et al. 15 with commercial kits (Boehringer Mannheim, Mi- 
lan, Italy). The intraassay and interassay variation coeffi- 
cients were 5.9% and 7.8%, respectively. 
Statistics. If not otherwise indicated, all data are given 
means + 1 SD of n experiments. The receptor numbers 
and the dissociation constants at each time were compared 
by analysis of variance and Student's t test for paired or 
unpaired ata. Plasma FPA concentrations in the various 
groups tudied were compared by the Kruskal-Wallis test. 
Correlation between FPA concentrations and platelet 
receptor number in the whole population was estimated by 
Kendall and Spearman rank correlation. All statistical 
analyses were performed with BMDP (Los Angeles, Calif.) 
statistical software. 
RESULTS 
12SI-PTA-OH binding to platelets. 125I-PTA-OH 
bound to platelets from control subjects with a Bma= 
of 303 _+ 83 fmol/10 s platelets, corresponding to 
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Fig. 2. Number of TxA2/PGH2 receptors per platelet in 
control subjects and in patients with unstable angina (UA) 
or stable effort angina (EA). 
1830 + 498 sites/platelet, and with a Kd of 30 _+ 7 
nmol/L (Fig. 1). In comparison, in patients with 
active unstable angina the number of binding sites 
was significantly greater (Bmax = 539 + 188 with 
3247 + 1132 sites/platelet, p < 0.001; Kd 30.5 _+ 6 
nmol/L, difference not significant [NS] (Figs. 1 and 
2) and was greater than that in patients with stable 
effort angina (Bma~ = 364-+ 58 fmol/10 s platelets 
with 2194 + 349 sites/platelet, p < 0.001; Kd = 30 
+ 9 nmol/L, NS), whose results did not significantly 
differ from those of control subjects. The increased 
number of platelet binding sites for TxA2/PGH2 
found in patients with active unstable angina was not 
associated with changes of affinity, as indicated by 
the lack of differences in KG. 
In patients with inactive unstable angina the 
number of binding sites (Bmax = 313 _+ 96 fmol/10 s
platelets with 1889 + 577 sites/platelet) was lower 
than that of patients with active angina (p < 0.001) 
and was similar to that of control subjects (Figs. 1 and 
2). In particular, in all 10 patients initially studied in 
the active phase and studied again in the inactive 
phase the number of binding sites was significantly 
reduced (from 2895 _+ 735 sites/platelet, Bmax = 
480 + 122 fmol/10 s platelets to 1688 _+ 471 sites/ 
platelet, Bmax = 280 _+ 78 fmol/10 s platelets; 
p < 0.002) and was not different from that of control 
subjects (Fig. 3). On the contrary no significant 
changes were observed when patients with effort an- 
gina and control subjects were studied again 8 to 12 
weeks later (Fig. 3). 
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Fig. 3. Number of TxA2/PGH2 receptors per platelet in 
patients with unstable angina studied in active phase (A) 
and 8 to 12 weeks later in inactive phase (B). Patients with 
effort stable angina and control subjects also were studied 
at baseline (A) and 8 to 12 weeks later (B). 
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Fig. 4. Spearman rank correlation (rs) between plasma 
FPA concentrations and number of TxA2/PGH2 receptors 
per platelet in all subjects (n = 83). 
All patients with active unstable angina showed 
increased thrombin generation, as indicated by in- 
creased plasma FPA concentrations. Plasma FPA 
levels in patients with active unstable angina 
(8.34 + 3.96, median 8.39, range 2.1 to 14.9 ng/ml) 
were significantly higher than those in control sub- 
jects (1.79 _+ 0.69, median 1.79, range 0.8 to 3.4 
ng/ml; z = 6.04, p < 0.05) or those in patients with 
effort angina (1.97 ___ 0.99, median 1.97, range 0.6 to  
4.3 ng/ml; z = 4.36, p < 0.05). In patients with inac- 
tive unstable angina the plasma FPA concentrations 
were lower than those in patients in the active phase 
(z = 4.72, p < 0.05) and were similar to those in con- 
trol subjects (2.17 + 1.21, median 2.17, range 1 to 5 
ng/ml). In particular all 10 patients with active 
angina studied again 8 to 12 weeks later in the inac- 
tive phase showed a significant reduction of plasma 
FPA concentrations (from median 7.92, range 2.2 to 
12.3 ng/ml to median 1.96, range 0.6 to 4.2 ng/ml; 
p = 0.003), at this time not differing from control 
subjects. A significant correlation was observed be- 
tween the plasma FPA concentrations and the TxA2/ 
PGH2 receptor number (n = 83, Kendall rank corre- 
lation coefficient =0.32, p < 0.01; Spearman rank 
correlation coefficient = 0.44, p < 0.001) (Fig. 4). 
No differences in the platelet count was observed 
among the different groups (Table I). Patients with 
active unstable angina had an higher percentage of 
megathrombocytes when compared with patients 
with effort angina and to controls (Table I). 
Effect of heparin infusion on 1251-PTA-OH binding in 
unstable angina. Heparin infusion significantly de- 
creased the plasma FPA concentrations in all pa- 
tients (from 8.61 _+ 1.96 to 2.07 + 1.21 ng/ml, 
p < 0.0001), with a parallel reduction in platelet 
TxA2/PGH2 binding sites (from 3407 _+ 901 sites/ 
platelet o 1819 + 266 sites/platelet, p < 0.001). The 
affinity of the binding sites was not significantly 
changed (Kd from 29.6 _+ 8.6 to 26.9 + 5.6 nmol/L, 
NS). On the contrary in none of the patients treated 
with aspirin did the number of platelet TxA2/PGH2 
receptors decrease (from 3500 _+ 527 to 3498 + 577 
sites/platelet, NS). In five of eight patients the n5I- 
PTA-OH binding capacity was even increased (Fig. 
5). 
Effects of thrombin and heparin on 1251-PTA-OH bind- 
ing in vitro. To investigate whether thrombin may be 
involved in the increased exposition of TxA2/PGH2 
platelet binding sites, normal platelets were incu- 
bated with increasing concentrations of thrombin. 
After a 10-minute incubation thrombin induced a 
significant increase in platelet 125I-PTA-OH binding. 
The number of receptors increased from 1889 _+ 798 
sites/platelet in a control sample to 3534 + 1033 
sites/plateiet (p < 0.01) in platelets incubated with 
thrombin 0.05 U/ml (Fig. 6). On the contrary hepa- 
rin in concentrations <2 IU/ml affected neither the 
number nor the affinity of platelet TxAu/PGH2 
receptors. In the presence of heparin 2 IU/ml the re- 
ceptor number passed from 2160 _+ 414 to 2223 _+ 
452 sites/platelet (NS). 
DISCUSSION 
The current results indicate that the number of 
platelet TxA2/PGH2 receptors was significantly in- 
creased in patients with active unstable angina but 
not in patients with inactive angina in comparison 
with control subjects and patients with effort angina, 
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and that enhanced thrombin formation seems to be 
responsible for the increased number of platelet 
TxA2/PGH2 receptors. The increased TxA2/PGH2 
binding density in patients with active unstable an- 
gina was confined to the active phase of disease be- 
cause the number of binding sites was similar to that 
in control subjects when the same patients were 
studied 8 to 12 weeks later, in the inactive phase of 
the disease. 
The increase in platelet binding sites might only be 
apparent in relation to the increased number of 
megathrombocytes found in current and previous 
studies.4, 5 16 In patients with active unstable angina, 
however, the average increase (3.3 %) in megathrom- 
bocytes in patients with active unstable angina is not 
enough to justify the increased number of TxA2/ 
PGH2 binding sites/platelet (from 6.8% in control 
subjects to 10.1% in patients with angina). In fact 
TxA2/PGH2 receptors were found on average at 1830 
sites/platelet in control subjects; even if the mega- 
thrombocy~es from patients with unstable angina 
had a number of receptors 10 times higher than that 
of platelets, the average number of binding sites per 
platelet could increase no more than 25 % instead of 
the 75 % found {from 1830 _ 498 in control subjects 
to 3247 7- 1132 sites/platelet in patients with angi- 
na). Moreover, heparin infusion did not significantly 
change the number of megathrombocytes but quickly 
induced asignificant decrease in platelet binding ca- 
pacity. It is stressed that this finding cannot be the 
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result of a direct effect of heparin on platelet binding 
sites because heparin in vitro did not affect TxA2/ 
PGH2 receptors. Therefore the increased number of 
TxA2/PGH2 receptors in patients with active unsta- 
ble angina ctually results from enhanced exposition 
of platelet binding sites. 
Increased thrombin generation seems to be respon- 
sible for the enhanced number of TxA2/PGH2 plate- 
let receptors. This hypothesis  supported by (1) the 
normality of TxA2/PGH2 receptor number in pa- 
tients with normal plasma FPA concentrations; (2) 
the close relation between FPA concentration i
plasma nd TxA2 receptor number; (3) the decrease 
in TxA2/PGH2 receptor number after heparin ad- 
ministration simultaneously with the decrease in 
thrombin formation, as indicated by the reduction in 
the plasma FPA concentrations; and (4) the capabil- 
ity of low or very low thrombin concentrations to in- 
duce in vitro an increase in the number of TxA2/ 
PGH2 receptors in platelets from controls, whereas 
heparin did not affect TxA2/PGH2 binding sites. 
These arguments strongly indicate a causative role 
for thrombin. 
Thrombin exerts various effects on the cell mem- 
brane, modifying the phospholipid composition by 
direct activation of phopholipases (A2, C, and D) 17 
and modifying the physical array of the lipidic leaf- 
let as a consequence of the enhanced aminophospho- 
lipid translocase activity, ls'19 Moreover thrombin 
induces release of lysophosphatidylcholine from 
plasma membrane at the same concentration found 
to enhance in vitro exposition of TxA2/PGH2 plate- 
let receptors. 2°This phospholipid fraction contains 
polyunsaturated fatty acid, especially docosa- 
hexaenoic acid (22:6n-3) and eicosapentaenoic acid 
(20:5n-3), that play a relevant role in the modulation 
of the TxA2/PGH2 receptor exposition and func- 
tion. 21,22 In thrombin-stimulated platelets 20:5n-3 
and 22:6n-3 are released from most of the phosphati- 
dylcholine fractions. 23 A previous tudy by our group 9
demonstrated that 20:5n-3 and 22:6n-3 were signifi- 
cantly reduced in membrane phospholipid fractions, 
especially in the phosphatidylcholine of platelets 
from patients with active unstable angina. Thus 
thrombin can enhance xposition of TxA2/PGH2 re- 
ceptors on the platelet membrane by reducing the 
membrane's content of polyunsaturated fatty acid. 
Another mechanism underlying the increased num- 
ber of the platelet TxA2/PGH2 receptors may be the 
oxidation of platelet membrane with formation of 
disulphide bonds during the passage of the platelet 
through myocardial ischemic areas. The formation of 
disulfide bonds has been found to increase rapidly 
the number of TxA2/PGH2 receptors. 24
The current results have important pathophysio- 
logic and therapeutic mplications. From the patho- 
physiologic point of view the increased number of 
TxA2/PGH2 platelet receptors can further favor 
platelet aggregation and thrombus formation in pa- 
tients with active unstable angina by means of 
enhanced TxA2 formation by platelets 25-27 and acti- 
vated monocytes. 2s The therapeutic implications 
seem to be more relevant because the causative role 
of thrombin in the enhancement of platelet binding 
sites can be better controlled by anticoagulant drugs 
rather than by antiaggregating drugs. Aspirin inhib- 
its platelet aggregation by blocking TxA2 synthesis 
but has little effect on thrombin-induced platelet ag- 
gregation and in the current study was unable to re- 
duce the increased 125I-PTA-OH binding capacity. 
Heparin in contrast is able to inhibit thrombin for- 
mation and thrombin-induced platelet activation. 
This assessment is supported by both the demon- 
strated efficacy of heparin in controlling myocardial 
ischemia in the active unstable angina 29, 30 and by the 
observation that heparin prevents myocardial infarc- 
tion better than does aspirin during the acute phase 
of unstable angina. 31 Thus heparin or specific TxA2/ 
PGH2-receptor-blocking agents eem to be prefera- 
ble to aspirin for the treatment ofpatients with acute 
unstable angina. 
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